Quantcast

Latest Liraglutide Stories

2014-07-17 04:21:04

MT Services LLC informs plaintiffs on various pharmaceutical drug cases available to obtain lawsuit funding and legal assistance BRONX, N.Y., July 17, 2014 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company, which operates lawsuitsettlementnews.com announced today a primary focus on assisting plaintiffs of bad pharmaceutical drugs such as AndgroGel: Testosterone Creams, Accutane, Acetaminophen, Actos, Avandia, Byetta-Januvia-Victoza, Birth Control Products:...

2014-07-07 12:28:53

Agents That Can Elicit Greater Weight Loss Remain a Key Unmet Need for Both Physicians and Payers, According to Findings from Decision Resources Group BURLINGTON, Mass., July 7, 2014 /PRNewswire/ -- Decision Resources Group finds that Novo Nordisk's fixed-dose combination (FDC) therapy insulin degludec/liraglutide (Xultophy, formerly known as IDegLira) is set to become the clinical gold-standard among FDCs used to treat patients with type 2 diabetes. The competitive advantages that this...

2014-07-05 23:01:25

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer, due to their use of the Type 2 diabetes medication. New York, NY (PRWEB) July 05, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to...

2014-06-27 04:21:25

Pre-Settlement Case Funding Firm announces new program focus for plaintiffs of Byetta, as well as Actos, Januvia, and Victoza cases. LOS ANGELES, June 27, 2014 /PRNewswire/ -- Legal-Bay LLC, the Lawsuit Settlement Funding Company, disclosed today a new lawsuit cash advance program that helps clients with cases facing Byetta complications. In 2011, after California medical researchers discovered that patients using Byetta are 3 times more at risk for Pancreatic cancer, the number of...

2014-06-25 08:26:32

Dominique's Diabetes Dream Team gives insider tips to people with type 2 diabetes through a national campaign and his "Diabetes Coaches' Clipboard" PLAINSBORO, N.J., June 25, 2014 /PRNewswire/ -- Novo Nordisk is teaming up with NBA great and Hall of Famer Dominique Wilkins to launch Dominique's Diabetes Dream Team, a national initiative to help adults with type 2 diabetes customize a full-court approach to managing the everyday challenges of the disease....

2014-06-14 12:21:08

PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus(®) (insulin glargine). Lowering of post-prandial glucose was measured as change...

2014-06-14 12:20:53

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Data from a new phase 3 study demonstrated that once-daily Victoza(R) (liraglutide [rDNA origin] injection) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment.[1],[2] The data were presented today at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, CA. Renal impairment is one of the more...

2014-06-14 12:20:45

Once-Weekly Dulaglutide 1.5 mg Also Demonstrates Weight Loss, Low Rates of Hypoglycemia in AWARD-6 Trial SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today released detailed results from dulaglutide's sixth AWARD trial, showing that once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg. The non-inferiority study demonstrated similar reductions in average blood sugar levels (HbA1c) across both arms.(1) The head-to-head study compared...

2014-06-14 12:20:36

SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- New Phase 3a findings show IDegLira, the investigational once-daily single injection combination of insulin degludec and liraglutide, for the treatment of people with type 2 diabetes, maintained its glucose-lowering effect and confirmed safety evaluations for up to one year.[1] Findings from the 26-week extension of the DUAL(TM) I clinical trial programme were presented today at the 74th Annual Scientific Sessions of the American...

2014-06-14 12:20:29

Data also showed liraglutide 3 mg improved blood glucose control compared to placebo at 56 weeks SAN FRANCISCO, June 14, 2014 /PRNewswire/ -- Today, primary results from SCALE(TM) Diabetes, a phase 3a clinical trial of liraglutide 3 mg, an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue for chronic weight management, were presented for the first time at the 74th Annual Scientific Sessions of the American Diabetes Association (ADA) in San Francisco,...


Word of the Day
lambent
  • Licking.
  • Hence Running along or over a surface, as if in the act of licking; flowing over or along; lapping or bathing; softly bright; gleaming.
This word comes the Latin 'lambere,' to lick.
Related